SYNGENE INTERNATIONAL LTD
Latest filings
- Syngene Q2 profit rebounds and wins first Bayview manufacturing deal · Investor Communications
- Three senior leaders leave Syngene, including strategy head Ajay Tandon · Management Changes
- Q2 FY27 revenue rises 13% from Q1; operating EBITDA margin improves to 18% · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates as a global Contract Research, Development and Manufacturing Organization (CRDMO), providing outsourced research, development and manufacturing services to pharmaceutical and biotechnology companies. Works with around 400 global customers and runs a workforce of over 8,300 employees. The business spans small-molecule CDMO work and a large-molecule / biologics CDMO (LMCDMO) franchise, supported by a material subsidiary, Syngene Scientific Solutions Limited, and the recently strengthened Syn.AI platform. FY26 revenue stood at Rs 3,738.7 crore with an EBITDA margin of 24.4%, but Q1 FY27 revenue fell 16% year-on-year to Rs 736 crore and EBITDA margin compressed to 12%, driven by lower offtake from a major biologics client and forex hedge losses. Employee costs are the largest expense at 29.6% of revenue, followed by materials at 24.4%, other operating expenses at 21.3% and depreciation at 12.1%, with capex running at 9.2% of revenue.
Scorecard
Measured from the filed financials, judged against its Healthcare Services peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SYNGENE INTERNATIONAL LTD's filed financials and exchange disclosures
What does SYNGENE INTERNATIONAL LTD do?
SYNGENE INTERNATIONAL LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol SYNGENE.
Is SYNGENE INTERNATIONAL LTD profitable?
Yes. Over the trailing twelve months SYNGENE INTERNATIONAL LTD reported a net profit of ₹221 Cr on revenue of ₹3,600 Cr.
Does SYNGENE INTERNATIONAL LTD pay a dividend?
Yes. The dividend yield is 0.34% at the current price. It paid out 16% of its profit as dividend in FY26.
Is SYNGENE INTERNATIONAL LTD debt-free?
On a net basis, yes. It reported borrowings of ₹9.40 Cr on its 31 Mar 2026 balance sheet, but holds ₹219 Cr more cash than debt.
Is SYNGENE INTERNATIONAL LTD expensive compared with its peers?
On trailing P/E, SYNGENE INTERNATIONAL LTD ranks 52 of 63 in Healthcare Services — cheaper than 18% of them, against an industry median of 35.6×. This is a position, not a valuation judgement.
How much does the SYNGENE INTERNATIONAL LTD share price move in a day?
On a typical session SYNGENE INTERNATIONAL LTD moves 1.15% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SYNGENE INTERNATIONAL LTD's announcements?
Every NSE and BSE filing by SYNGENE INTERNATIONAL LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.